The results of a systematic review support the interchangeability of biosimilar tumor necrosis factorα (TNF)-α inhibitors with their respective reference biologics in treating rheumatoid arthritis, inflammatory bowel disease, and psoriasis.

Together with the European Renal Association−European Dialysis and Transplant Association (ERA-EDTA), the European League Against Rheumatism (EULAR) has published updated recommendations for the management of patients with antineutrophil cytoplasmic antibody−associated vasculitis.

Patients with rheumatoid arthritis (RA) taking tocilizumab have a higher rate of lower intestinal perforations (LIPs) compared with patients taking conventional synthetic and other biologic disease-modifying antirheumatic drugs (DMARDs), according to results of a recent, comprehensive, registry-based study by Anja Strangfeld, MD, Department of Epidemiology, German Rheumatism Research Centre, Berlin, and colleagues.

An estimated 7.5 million people in the United States have psoriasis, a chronic, inflammatory, autoimmune disease. Psoriasis is characterized by thick patches of inflamed, scaly skin resulting from excessive proliferation of skin cells. The disease typically affects the scalp, knees, elbows, hands, feet, lower back, and joints; it can also affect nails, the soft tissues of the genitals, and the inside of the mouth. In some cases, psoriasis can lead to disfigurement and disability.